Supplementary Figure 2 from A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma

<p>Cell type predictive of treatment efficacy. Cell type differences of (a) partial response vs non-partial responders (b) progression-free survival longer vs shorter than 6 months by MCP-Counter. All p-values were derived from non-parametric Wilcoxon test.</p>

-д хадгалсан:

Номзүйн дэлгэрэнгүй
Үндсэн зохиолч:	Tom Wei-Wu Chen (15053003) (author)
Бусад зохиолчид:	Chia-Lang Hsu (11929719) (author), Ruey-Long Hong (15053006) (author), Jen-Chieh Lee (14954275) (author), Koping Chang (15053009) (author), Chih-Wei Yu (15053012) (author), San-Chi Chen (15050106) (author), Jhe-Cyuan Guo (15053015) (author), Mei-Lu Chen (15053018) (author), Meng-Chi Hsu (15053021) (author), Ting-Fang Kung (15053024) (author), Ann-Lii Cheng (15045786) (author), Chueh-Chuan Yen (15053027) (author)
Хэвлэсэн:	2025
Нөхцлүүд:	Cancer Therapeutic Research and Development Clinical Research and Trials Clinical Trial Results Phase II clinical trials Sarcomas Soft-tissue sarcoma Translational Research
Шошгууд:	Шошго нэмэх Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!

Supplementary Figure 2 from A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma

Ижил төстэй зүйлс